301 related articles for article (PubMed ID: 32330228)
21. Genome Surgery and Gene Therapy in Retinal Disorders.
Chan L; Mahajan VB; Tsang SH
Yale J Biol Med; 2017 Dec; 90(4):523-532. PubMed ID: 29259518
[TBL] [Abstract][Full Text] [Related]
22. Gene Therapy for Inherited Retinal Degeneration.
Arbabi A; Liu A; Ameri H
J Ocul Pharmacol Ther; 2019 Mar; 35(2):79-97. PubMed ID: 30688548
[TBL] [Abstract][Full Text] [Related]
23. Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa.
Xi Z; Vats A; Sahel JA; Chen Y; Byrne LC
Nat Commun; 2022 Dec; 13(1):7695. PubMed ID: 36509783
[TBL] [Abstract][Full Text] [Related]
24. Gene Editing for
Pierce EA; Aleman TS; Jayasundera KT; Ashimatey BS; Kim K; Rashid A; Jaskolka MC; Myers RL; Lam BL; Bailey ST; Comander JI; Lauer AK; Maguire AM; Pennesi ME
N Engl J Med; 2024 Jun; 390(21):1972-1984. PubMed ID: 38709228
[TBL] [Abstract][Full Text] [Related]
25. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
[TBL] [Abstract][Full Text] [Related]
26. Clustered Regularly Interspaced Short Palindromic Repeats-Based Genome Surgery for the Treatment of Autosomal Dominant Retinitis Pigmentosa.
Tsai YT; Wu WH; Lee TT; Wu WP; Xu CL; Park KS; Cui X; Justus S; Lin CS; Jauregui R; Su PY; Tsang SH
Ophthalmology; 2018 Sep; 125(9):1421-1430. PubMed ID: 29759820
[TBL] [Abstract][Full Text] [Related]
27. Toward genome editing in X-linked RP-development of a mouse model with specific treatment relevant features.
Schlegel J; Hoffmann J; Röll D; Müller B; Günther S; Zhang W; Janise A; Vössing C; Fühler B; Neidhardt J; Khanna H; Lorenz B; Stieger K
Transl Res; 2019 Jan; 203():57-72. PubMed ID: 30213530
[TBL] [Abstract][Full Text] [Related]
28. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
29. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
30. Personalized therapeutic strategies for patients with retinitis pigmentosa.
Zheng A; Li Y; Tsang SH
Expert Opin Biol Ther; 2015 Mar; 15(3):391-402. PubMed ID: 25613576
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
32. Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.
Beltran WA; Cideciyan AV; Boye SE; Ye GJ; Iwabe S; Dufour VL; Marinho LF; Swider M; Kosyk MS; Sha J; Boye SL; Peterson JJ; Witherspoon CD; Alexander JJ; Ying GS; Shearman MS; Chulay JD; Hauswirth WW; Gamlin PD; Jacobson SG; Aguirre GD
Mol Ther; 2017 Aug; 25(8):1866-1880. PubMed ID: 28566226
[TBL] [Abstract][Full Text] [Related]
33. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
34. Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
Diakatou M; Manes G; Bocquet B; Meunier I; Kalatzis V
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126147
[No Abstract] [Full Text] [Related]
35. Genome Editing for Inherited Retinal Degenerations.
Pierce E
Ophthalmology; 2018 Sep; 125(9):1431-1432. PubMed ID: 30143094
[No Abstract] [Full Text] [Related]
36. Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice.
Song C; Conlon TJ; Deng WT; Coleman KE; Zhu P; Plummer C; Mandapati S; Van Hoosear M; Green KB; Sonnentag P; Sharma AK; Timmers A; Robinson PM; Knop DR; Hauswirth WW; Chulay JD; Shearman MS; Ye GJ
Hum Gene Ther Clin Dev; 2018 Dec; 29(4):188-197. PubMed ID: 30280954
[TBL] [Abstract][Full Text] [Related]
37. CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.
Burnight ER; Giacalone JC; Cooke JA; Thompson JR; Bohrer LR; Chirco KR; Drack AV; Fingert JH; Worthington KS; Wiley LA; Mullins RF; Stone EM; Tucker BA
Prog Retin Eye Res; 2018 Jul; 65():28-49. PubMed ID: 29578069
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa.
Beltran WA; Cideciyan AV; Lewin AS; Iwabe S; Khanna H; Sumaroka A; Chiodo VA; Fajardo DS; Román AJ; Deng WT; Swider M; Alemán TS; Boye SL; Genini S; Swaroop A; Hauswirth WW; Jacobson SG; Aguirre GD
Proc Natl Acad Sci U S A; 2012 Feb; 109(6):2132-7. PubMed ID: 22308428
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa.
Michalakis S; Koch S; Sothilingam V; Garcia Garrido M; Tanimoto N; Schulze E; Becirovic E; Koch F; Seide C; Beck SC; Seeliger MW; Mühlfriedel R; Biel M
Adv Exp Med Biol; 2014; 801():733-9. PubMed ID: 24664765
[TBL] [Abstract][Full Text] [Related]
40. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
